INCREASED NUMBERS OF CIRCULATING BASOPHILS WITH DECREASED RELEASABILITY AFTER ADMINISTRATION OF RHG-CSF TO ALLERGIC PATIENTS

被引:2
|
作者
PEDERSEN, M
KRISTENSEN, KS
CLEMENTSEN, P
OLSEN, OT
SKOV, PS
PERMIN, H
NORN, S
机构
[1] GENTOFTE UNIV HOSP,DEPT PULM DIS,HELLERUP,DENMARK
[2] REFERENCE LAB,COPENHAGEN,DENMARK
[3] UNIV COPENHAGEN,DEPT PHARMACOL,COPENHAGEN,DENMARK
来源
AGENTS AND ACTIONS | 1994年 / 41卷
关键词
D O I
10.1007/BF02007750
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Preliminary studies in hematological patients have indicated that treatment with rhG-CSF reduces basophil releasability ex vivo. We examined this phenomenon further, in allergic patients. Ten patients with grass pollen rhinoconjunctivitis were given rhG-CSF (5 mu g/kg/day s.c.) for 5 days, and examined before and after treatment. Basophil counts increased from 5 to 19 x 10(9)/1 (P < 0.01). Total blood histamine increased from 80 to 160 mu g/l (P < 0.01), corresponding to a decrease in average basophil histamine content from 1.5 to 0.81 pg/cell (P < 0.01). Isolated mononuclear cells showed a significantly decreased histamine release (HR) when stimulated with A23187 and grass. Whole blood experiments showed a similar decreased HR to grass and anti-IgE (P < 0.01). However, we found an increase in total blood histamine. We conclude that treatment with rhG-CSF (1) increases the number of circulating blood basophils, (2) reduces the average histamine content per basophil, and (3) reduces the basophil releasability. These findings could be due to the mobilization of immature basophils from the bone marrow.
引用
收藏
页码:C24 / C25
页数:2
相关论文
共 43 条
  • [31] A multicenter phase II trial of primary prophylactic PEG- rhG-CSF in pediatric patients with solid tumors and non- Hodgkin lymphoma after chemotherapy: An interim analysis
    Huang, Junting
    Lu, Suying
    Wang, Juan
    Jiang, Lian
    Luo, Xuequn
    He, Xiangling
    Wu, Yanpeng
    Wang, Yi
    Zhu, Xiuli
    Chen, Jian
    Tang, Yanlai
    Chen, Keke
    Tian, Xin
    Shi, Boyun
    Guo, Lanying
    Zhu, Jia
    Sun, Feifei
    Zhen, Zijun
    Zhang, Yizhuo
    CANCER MEDICINE, 2023, 12 (13): : 14130 - 14137
  • [32] NEUTROPHIL FUNCTION IN NONALCOHOLIC CIRRHOTIC-PATIENTS BEFORE AND AFTER ADMINISTRATION OF RECOMBINANT COLONY-STIMULATING FACTORS (RHG AND RHGM-CSF)
    DARUICH, J
    FINDOR, J
    CARBIA, C
    DIAZ, B
    CALAHONRA, C
    MANERO, E
    AVALOS, JS
    HEPATOLOGY, 1994, 20 (04) : A342 - A342
  • [33] Increased numbers of bone marrow blasts in acute myeloid leukaemia patients treated with G-CSF after chemotherapy
    Kaddar, A
    Edinger, M
    Wirth, K
    Schaefer, HE
    Lubbert, M
    Lindemann, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (02) : 492 - 493
  • [34] Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
    Gao, Lei
    Zhang, Yanqi
    Wang, Sanbin
    Kong, Peiyan
    Su, Yi
    Hu, Jiong
    Jiang, Ming
    Bai, Hai
    Lang, Tao
    Wang, Jishi
    Liu, Li
    Yang, Tonghua
    Huang, Xiaobing
    Liu, Fang
    Lou, Shifeng
    Liu, Yao
    Zhang, Cheng
    Liu, Hong
    Gao, Li
    Liu, Jia
    Zhu, Lidan
    Wen, Qin
    Chen, Ting
    Wang, Ping
    Rao, Jun
    Mao, Min
    Wang, Cunbang
    Duan, Xianlin
    Luo, Le
    Peng, Xiangui
    Cassady, Kaniel
    Zhong, Jiang F.
    Zhang, Xi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) : 4249 - +
  • [35] INCREASED FREQUENCY OF COMPLETE REMISSION BY LENOGRASTIM RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) ADMINISTRATION AFTER INTENSIVE INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS WITH DE-NOVO ACUTE MYELOID-LEUKEMIA (AML) - FINAL RESULTS OF A RANDOMIZED MULTICENTER DOUBLE-BLIND CONTROLLED-STUDY
    DOMBRET, H
    YVER, A
    CHASTANG, C
    DEGOS, L
    BLOOD, 1994, 84 (10) : A231 - A231
  • [36] A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
    Zhang, Qingyuan
    Wang, Zhonghua
    Yao, Wei
    Wang, Shufang
    Zhang, Gaochong
    Chen, Jianmin
    Hou, Qingsong
    Li, Simon
    Li, Hongsheng
    Ye, Changsheng
    Sun, Tao
    Yang, Hongjian
    Chen, Zhendong
    Wang, Zhihong
    Liu, Xiaoan
    Geng, Cuizhi
    Li, Xingrui
    Zhang, Jin
    Zheng, Hong
    Shao, Zhimin
    BMC CANCER, 2024, 24 (01)
  • [37] Decreased Superoxide Dismutase Concentrations (SOD) in Plasma and CSF and Increased Circulating Total Antioxidant Capacity (TAC) Are Associated with Unfavorable Neurological Outcome after Aneurysmal Subarachnoid Hemorrhage
    Krenzlin, Harald
    Wesp, Dominik
    Schmitt, Jan
    Frenz, Christina
    Kurz, Elena
    Masomi-Bornwasser, Julia
    Lotz, Johannes
    Ringel, Florian
    Kerz, Thomas
    Keric, Naureen
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 10
  • [38] INCREASED NUMBERS OF CIRCULATING HEMATOPOIETIC PROGENITOR CELLS AFTER TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 IN CANCER-PATIENTS
    SCHAAFSMA, MR
    FIBBE, WE
    VANDERHARST, D
    DUINKERKEN, N
    BRAND, A
    OSANTO, S
    FRANKS, CR
    WILLEMZE, R
    FALKENBURG, JHF
    BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (02) : 180 - 185
  • [39] A randomized, multicenter phase III study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting dimeric rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
    Daley, William
    Shao, Zhimin
    Zhang, Qingyuan
    Li, Hongshen
    Ye, Changshen
    Wang, Shufang
    Zhang, Langxi
    Zhang, Gaochong
    Chen, Jianmin
    CANCER RESEARCH, 2022, 82 (04)
  • [40] rhGM-CSF-treated burn patients demonstrate enhanced PMN apoptosis and circulating soluble FAS-ligand (sFAS-L) levels after an increase in PMN numbers and function.
    Pellegrin, K
    Peterson, VM
    Liles, WC
    Kiener, PA
    Ambruso, DR
    BLOOD, 1998, 92 (10) : 378A - 378A